Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) has taken a step further in its bid to establish next-generation psychedelic medicines to treat mental illness, announcing that three of its patent applications for candidates had been published by the Patent Cooperation Treaty (PCT).
The three patent applications cover a range of the firm's so-called Family 1 and Family 2 compounds designed to deliver superior therapeutic benefits to psilocybin with lower overall metabolic and safety liabilities.
READ: Mindset Pharma reveals new results indicating its psychedelic analogs have greater efficacy and shorter durations compared with reference drugs
"The publication of our PCT patent applications reaffirms the novelty of our approach and first-to-file advantage," James Lanthier, CEO of Mindset, told investors in a statement.
"We continue to run in vitro and in vivo tests on these patent-pending compounds to further validate their superior efficacy and safety profile."
Mindset’s Family 1 compounds use modern drug design using conjugated and deuterated psilocybin and psilocin design strategies to improve on psilocybin’s potential toxicity and pharmacokinetics profile.
The Family 2 compounds are next-generation psilocybin and psilocin drug candidates optimized for in-clinic settings.
The biotech said it had run a battery of highly specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.
Contact the author at giles@proactiveinvestors.com